alanine has been researched along with Carcinoma, Anaplastic in 21 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with metastatic colorectal cancer previously treated with combination chemotherapy were randomly assigned 1:1 to receive cetuximab 400 mg/m(2) intravenous loading dose followed by weekly maintenance of 250 mg/m(2) plus either brivanib 800 mg orally daily (arm A) or placebo (arm B)." | 9.17 | Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr ( Charpentier, D; Couture, F; Haydon, A; Jefford, M; Jonker, DJ; Karapetis, CS; Liauw, W; Magoski, NM; Moore, MJ; Nott, LM; O'Callaghan, CJ; Price, TJ; Ringash, J; Sawyer, MB; Shapiro, JD; Siddiqui, J; Simes, J; Siu, LL; Tu, D; Walters, I; Zalcberg, JR, 2013) |
| "The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy." | 8.02 | The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. ( Avilés-Jurado, FX; León, X; Pardo, L; Quer, M; Sansa, A; Terra, X; Valero, C; Venegas, MDP, 2021) |
| "The human colon carcinoma cell line HT-29, when grown to confluence, was found to take up taurine and accumulate it against a concentration gradient from a NaCl-containing uptake medium." | 7.68 | Constitutive expression of the taurine transporter in a human colon carcinoma cell line. ( Brandsch, M; Ganapathy, V; Leibach, FH; Miyamoto, Y; Tiruppathi, C, 1992) |
| "Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR)." | 6.84 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. ( Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS, 2017) |
| "Patients with metastatic colorectal cancer previously treated with combination chemotherapy were randomly assigned 1:1 to receive cetuximab 400 mg/m(2) intravenous loading dose followed by weekly maintenance of 250 mg/m(2) plus either brivanib 800 mg orally daily (arm A) or placebo (arm B)." | 5.17 | Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr ( Charpentier, D; Couture, F; Haydon, A; Jefford, M; Jonker, DJ; Karapetis, CS; Liauw, W; Magoski, NM; Moore, MJ; Nott, LM; O'Callaghan, CJ; Price, TJ; Ringash, J; Sawyer, MB; Shapiro, JD; Siddiqui, J; Simes, J; Siu, LL; Tu, D; Walters, I; Zalcberg, JR, 2013) |
| "Extrahepatic glucose release was evaluated during the anhepatic phase of liver transplantation in 14 recipients for localized hepatocarcinoma with mild or absent cirrhosis, who received a bolus of [6,6-2H2]glucose and l-[3-13C]alanine or l-[1,2-13C2]glutamine to measure glucose kinetics and to prove whether gluconeogenesis occurred from alanine and glutamine." | 5.11 | Nonhepatic glucose production in humans. ( Ammatuna, M; Battezzati, A; Caumo, A; Coppa, J; Luzi, L; Martino, F; Matthews, DE; Mazzaferro, V; Regalia, E; Romito, R; Sereni, LP, 2004) |
| "The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy." | 4.02 | The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. ( Avilés-Jurado, FX; León, X; Pardo, L; Quer, M; Sansa, A; Terra, X; Valero, C; Venegas, MDP, 2021) |
| "The human colon carcinoma cell line HT-29, when grown to confluence, was found to take up taurine and accumulate it against a concentration gradient from a NaCl-containing uptake medium." | 3.68 | Constitutive expression of the taurine transporter in a human colon carcinoma cell line. ( Brandsch, M; Ganapathy, V; Leibach, FH; Miyamoto, Y; Tiruppathi, C, 1992) |
| "Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR)." | 2.84 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. ( Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS, 2017) |
| "A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to improve the aqueous solubility and oral bioavailability of the parent compound." | 1.35 | Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth fa ( Barbosa, S; Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; D'Arienzo, C; Derbin, G; Fan, J; Fargnoli, J; Hunt, JT; Jeyaseelan, R; Kamath, A; Kukral, DW; Lombardo, LJ; Marathe, P; Mortillo, S; Qian, L; Robl, JA; Shi, Z; Wautlet, BS; Wei, D; Wu, L; Zhang, Y; Zheng, X, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (33.33) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Sansa, A | 1 |
| Venegas, MDP | 1 |
| Valero, C | 1 |
| Pardo, L | 1 |
| Avilés-Jurado, FX | 1 |
| Terra, X | 1 |
| Quer, M | 1 |
| León, X | 1 |
| Chan, JK | 1 |
| Deng, W | 1 |
| Higgins, RV | 1 |
| Tewari, KS | 1 |
| Bonebrake, AJ | 1 |
| Hicks, M | 1 |
| Gaillard, S | 1 |
| Ramirez, PT | 1 |
| Chafe, W | 1 |
| Monk, BJ | 1 |
| Aghajanian, C | 1 |
| You, W | 1 |
| Li, Z | 1 |
| Jing, C | 1 |
| Qian-Wei, X | 1 |
| Yu-Ping, Z | 1 |
| Weng-Guang, L | 1 |
| Hua-Lei, L | 1 |
| Siu, LL | 1 |
| Shapiro, JD | 1 |
| Jonker, DJ | 1 |
| Karapetis, CS | 1 |
| Zalcberg, JR | 1 |
| Simes, J | 1 |
| Couture, F | 1 |
| Moore, MJ | 1 |
| Price, TJ | 1 |
| Siddiqui, J | 1 |
| Nott, LM | 1 |
| Charpentier, D | 1 |
| Liauw, W | 1 |
| Sawyer, MB | 1 |
| Jefford, M | 1 |
| Magoski, NM | 1 |
| Haydon, A | 1 |
| Walters, I | 1 |
| Ringash, J | 1 |
| Tu, D | 1 |
| O'Callaghan, CJ | 1 |
| Zhang, Q | 1 |
| Gao, J | 1 |
| Li, L | 1 |
| Chen, HB | 1 |
| Li, XQ | 1 |
| Yan, XZ | 1 |
| Gusella, M | 1 |
| Bertolaso, L | 1 |
| Bolzonella, C | 1 |
| Pasini, F | 1 |
| Padrini, R | 1 |
| Shin, WG | 1 |
| Kim, SJ | 1 |
| Choi, MH | 1 |
| Kim, KO | 1 |
| Jang, HJ | 1 |
| Park, CH | 1 |
| Baek, IH | 1 |
| Kim, KH | 1 |
| Baik, GH | 1 |
| Kae, SH | 1 |
| Kim, JH | 1 |
| Kim, HY | 1 |
| Maxwell, SA | 1 |
| Rivera, A | 1 |
| Dalakas, MC | 1 |
| Dagvadorj, A | 1 |
| Goudeau, B | 1 |
| Park, KY | 1 |
| Takeda, K | 1 |
| Simon-Casteras, M | 1 |
| Vasconcelos, O | 1 |
| Sambuughin, N | 1 |
| Shatunov, A | 1 |
| Nagle, JW | 1 |
| Sivakumar, K | 1 |
| Vicart, P | 1 |
| Goldfarb, LG | 1 |
| Battezzati, A | 1 |
| Caumo, A | 1 |
| Martino, F | 1 |
| Sereni, LP | 1 |
| Coppa, J | 1 |
| Romito, R | 1 |
| Ammatuna, M | 1 |
| Regalia, E | 1 |
| Matthews, DE | 1 |
| Mazzaferro, V | 1 |
| Luzi, L | 1 |
| RIGGS, TR | 1 |
| WALKER, LM | 1 |
| KROMPHRADT, H | 1 |
| Kaufmann, R | 1 |
| Schulze, B | 1 |
| Krause, G | 1 |
| Mayr, LM | 1 |
| Settmacher, U | 1 |
| Henklein, P | 1 |
| Paynter, RA | 1 |
| Hankinson, SE | 1 |
| Colditz, GA | 1 |
| Hunter, DJ | 1 |
| De Vivo, I | 1 |
| Cai, ZW | 1 |
| Zhang, Y | 1 |
| Borzilleri, RM | 1 |
| Qian, L | 1 |
| Barbosa, S | 1 |
| Wei, D | 1 |
| Zheng, X | 1 |
| Wu, L | 1 |
| Fan, J | 1 |
| Shi, Z | 1 |
| Wautlet, BS | 1 |
| Mortillo, S | 1 |
| Jeyaseelan, R | 1 |
| Kukral, DW | 1 |
| Kamath, A | 1 |
| Marathe, P | 1 |
| D'Arienzo, C | 1 |
| Derbin, G | 1 |
| Barrish, JC | 1 |
| Robl, JA | 1 |
| Hunt, JT | 1 |
| Lombardo, LJ | 1 |
| Fargnoli, J | 1 |
| Bhide, RS | 1 |
| Tiruppathi, C | 1 |
| Brandsch, M | 1 |
| Miyamoto, Y | 1 |
| Ganapathy, V | 1 |
| Leibach, FH | 1 |
| Marcialis, MA | 1 |
| Schivo, ML | 1 |
| Cioglia, AM | 1 |
| Atzeni, A | 1 |
| Loddo, B | 1 |
| Spellman, CM | 1 |
| Fottrell, PF | 1 |
| Prage, L | 1 |
| Pettersson, U | 1 |
| Hahn, K | 1 |
| Ladner, HA | 1 |
| Jesdinsky, HJ | 1 |
| Ohno, R | 1 |
| Hersh, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)[NCT01267253] | Phase 2 | 31 participants (Actual) | Interventional | 2011-04-04 | Completed | ||
| A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbitux®) Versus Placebo in Combination With Cetuximab (Erbitux®) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for M[NCT00640471] | Phase 3 | 750 participants (Actual) | Interventional | 2008-05-12 | Completed | ||
| Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? : Multicenter, Randomized, and Prospective Study[NCT01167101] | 290 participants (Actual) | Interventional | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1 (NCT01267253)
Timeframe: Every other cycle for first 6 months; then every 3 months thereafter until disease progression confirmed; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.
| Intervention | proportion (Number) |
|---|---|
| Brivanib | 0.071 |
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.. (NCT01267253)
Timeframe: From study entry to time of death or the date of last contact, up to 5 years of follow-up.
| Intervention | Months (Median) |
|---|---|
| Brivanib | 7.9 |
Proportion of participants who survive progression-free for at least 6 months without non-protocol therapy from study entry. Progression is assessed by RECIST 1.1. (NCT01267253)
Timeframe: Every other cycle for first 6 months; then every 3 months therafter until disease progression confirmed; and at any other time if cliniclly indicated based on symptoms or physical signs suggestive of progressive disease
| Intervention | proportion (Number) |
|---|---|
| Brivanib | 0.179 |
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1 (NCT01267253)
Timeframe: From study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up
| Intervention | Months (Median) |
|---|---|
| Brivanib | 3.2 |
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v.4.0 (NCT01267253)
Timeframe: During treatment period and up to 30 days after stopping the study treatment.
| Intervention | Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukopenia | Thrombocytopenia | Neutropenia | Anemia | Other Investigations | Cardiac Disorders | Gastrointestinal Disorders | General disorders & administration site conditions | Hepatobiliary Disorders | Infections and infestations | Metabolism and nutrition disorders | Musculoskeletal & connective tissue disorders | Neoplasms benign, malignant & unspecified | Nervous system disorders | Renal and urinary disorders | Vascular Disorders | |
| Brivanib | 0 | 0 | 0 | 4 | 4 | 1 | 7 | 2 | 1 | 4 | 5 | 3 | 2 | 3 | 2 | 5 |
1 review available for alanine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
MTHFR C677T and A1298C polymorphisms were associated with bladder cancer risk and disease progression: a meta-analysis.
Topics: Alanine; Amino Acid Substitution; Carcinoma; Case-Control Studies; Cysteine; Disease Progression; Ge | 2013 |
4 trials available for alanine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma; Disease Progression; Dise | 2017 |
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr
Topics: Adult; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study.
Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Carcinoma; Chi-Square Distribution; Confidence Intervals; | 2012 |
Nonhepatic glucose production in humans.
Topics: Adult; Alanine; Blood Glucose; Carcinoma; Follow-Up Studies; Gluconeogenesis; Glutamine; Hepatectomy | 2004 |
16 other studies available for alanine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients.
Topics: Alanine; Alanine Transaminase; Aspartate Aminotransferases; Aspartic Acid; Biomarkers, Tumor; Carcin | 2021 |
[Metabonomic study of blood plasma in the assessment of liver graft function].
Topics: Acetone; Alanine; Biomarkers; Blood Glucose; Carcinoma; Choline; Glutamine; Humans; Lactic Acid; Liv | 2007 |
Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Amino Acid Substitution; Carcinoma; Chromatography, High Pr | 2011 |
Proline oxidase induces apoptosis in tumor cells, and its expression is frequently absent or reduced in renal carcinomas.
Topics: Alanine; Apoptosis; Arginine; Blotting, Western; Carcinoma; DNA, Complementary; Flow Cytometry; Gree | 2003 |
Progressive skeletal myopathy, a phenotypic variant of desmin myopathy associated with desmin mutations.
Topics: Alanine; Animals; Carcinoma; Cell Line; Cysteine; Desmin; DNA Mutational Analysis; Female; Fluoresce | 2003 |
ACTION OF ESTROGEN SULFATES ON ACCUMULATION OF AMINO ACIDS BY EHRLICH ASCITES TUMOR CELLS IN VITRO.
Topics: Alanine; Amino Acids; Aminoisobutyric Acids; Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Dinitroph | 1964 |
[THE UPTAKE OF TAURINE IN EHRLICH ASCITES TUMOR CELLS].
Topics: Alanine; Amino Acids; Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Glycine; Metabolism; Mice; Radio | 1963 |
Proteinase-activated receptors (PARs)--the PAR3 Neo-N-terminal peptide TFRGAP interacts with PAR1.
Topics: Alanine; Animals; Blotting, Western; Carcinoma; Cell Line, Tumor; Dose-Response Relationship, Drug; | 2005 |
No evidence of a role for PPARgamma Pro12Ala polymorphism in endometrial cancer susceptibility.
Topics: Alanine; Alleles; Amino Acid Substitution; Androstenedione; Aromatase; Carcinoma; Case-Control Studi | 2004 |
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth fa
Topics: Administration, Oral; Alanine; Animals; Biological Availability; Carcinoma; Cell Proliferation; Clin | 2008 |
Constitutive expression of the taurine transporter in a human colon carcinoma cell line.
Topics: Alanine; Biological Transport; Carcinoma; Carrier Proteins; Chlorides; Colonic Neoplasms; Culture Me | 1992 |
Irreversible impairment produced by guanidine on the functions of poliovirus proteins.
Topics: Alanine; Amines; Antiviral Agents; Carcinoma; Cell Line; Fluorine; Guanidines; Humans; Laryngeal Neo | 1973 |
Similarities between pyruvate kinase from human placenta and tumours.
Topics: Adenosine Triphosphate; Alanine; Carcinoma; Chromatography, Gel; Chromatography, Ion Exchange; Elect | 1973 |
Structural proteins of adenoviruses. VII. Purification and properties of an arginine-rich core protein from adenovirus type 2 and type 3.
Topics: Adenoviridae; Alanine; Amino Acids; Animals; Antigens; Arginine; Autoanalysis; Carcinoma; Cell Line; | 1971 |
[Concentration changes of free amino acids in blood plasma of patients under radiotherapy. (With reference to statistical results)].
Topics: Alanine; Amino Acids; Bronchial Neoplasms; Carcinoma; Cobalt Isotopes; Dysgerminoma; Esophageal Neop | 1972 |
Immunosuppressive effects of L-asparaginase.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Alanine; Antibody Formation; Antigens; Asparaginase; Asparagin | 1970 |